ArticleInfection2026
Impact of an antimicrobial stewardship intervention on carbapenem use in children with cancer.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeInfections during neutropenia are a potentially life-threatening complication in pediatric oncology. International guidelines recommend antipseudomonal β-lactam monotherapy for stable patients, however, modification to carbapenems often occurs without confirmed infection.
methodsWe conducted a retrospective cohort study at a single tertiary pediatric oncology center to assess the impact of a carbapenem-sparing AMS intervention in children during neutropenia. All pediatric cancer patients with at least one episode of suspected infection between January 2021 and October 2024 were included. The intervention combined training, updated standard operating procedures, multidrug-resistant (MDR) surveillance swabs, and a structured protocol reassessing meropenem treatment.
resultsAmong 254 patients, 116 met the inclusion criteria, accounting for 432 episodes (270 pre- and 162 post-intervention). Re-modification of antimicrobial therapy from meropenem to piperacillin/tazobactam was achieved in 16 of 50 post-intervention episodes. The median duration of meropenem treatment decreased from 9 to 6 days (p = 0.006). Interrupted time series analysis showed a non-significant reduction in meropenem use, corresponding to an estimated decline of 40.7 days of therapy (DOT) per 1000 patient-days per quarter. Mortality was unchanged (3.8% vs 4.3%).
conclusionOur findings demonstrate that a structured AMS intervention is feasible and effective in pediatric oncology, reducing unnecessary meropenem exposure without compromising safety. While this approach may serve as a model for broader multicenter efforts to promote individualized, evidence-based antimicrobial use, the low number of blood stream infections (BSI) in our cohort limits the ability to draw definitive conclusions about the clinical impact of MDR screening on infection-related outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.